drugset

drugset / Trial / NCT02185183

Oral Administration of AlequelTM for Patients With Inflammatory Bowel Disease (IBD)

NCT02185183 ↗

Phase 1/2 Completed 22 enrolled Hadassah Medical Organization

NaSingle-groupDouble-blindTreatment

Summary

Oral administration of Alequel, a mixture of proteins derived from the patient's bowel will be tested in patients with inflammatory bowel disease.

Timeline

Start: 2008-01
Primary completion: 2010-01
Completion: 2010-01

Drugs

Evaluation	Drug	Modality	Dose	Route
Subject	Alequel	Protein / enzyme biologic	—	Oral

Indications